Total Funding
17
37
Total FundingVenture - Series Unknown raised
Growth Score
-37 pts
Heat Score
-6 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
65218
A Stockholm, Sweden-based biopharmaceutical company.
- David Berglund: CSO
David H. Sachs: CTO
About the Company
ITBMed is a biopharmaceutical company developing specific immunomodulatory biologics for organ transplantation, stem cell transplantation, and gene therapy. The lead candidate drug Siplizumab is a monoclonal antibody in late-stage clinical development, which has shown significant potential in transforming the life for organ transplant patients, by
allowing the complete discontinuation of all immunosuppression treatment and restoration of a normal life.
